Ian Goldlust
Ian Goldlust
Oncology Fellow, NIH/NCI
Verified email at
Cited by
Cited by
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
LA Mathews Griner, R Guha, P Shinn, RM Young, JM Keller, D Liu, ...
Proceedings of the National Academy of Sciences 111 (6), 2349-2354, 2014
Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes
MD Hall, KA Telma, KE Chang, TD Lee, JP Madigan, JR Lloyd, ...
Cancer research 74 (14), 3913-3922, 2014
Synthetic riboswitches that induce gene expression in diverse bacterial species
S Topp, CMK Reynoso, JC Seeliger, IS Goldlust, SK Desai, D Murat, ...
Applied and environmental microbiology 76 (23), 7881-7884, 2010
An automated fitting procedure and software for dose-response curves with multiphasic features.
GY Veroli, C Fornari, I Goldlust, G Mills, SB Koh, JL Bramhall, ...
Scientific reports 5, 14701-14701, 2015
Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency
T Wang, H Wu, Y Li, KE Szulwach, L Lin, X Li, IP Chen, IS Goldlust, ...
Nature cell biology 15 (6), 700-711, 2013
Mouse model implicates GNB3 duplication in a childhood obesity syndrome
IS Goldlust, KE Hermetz, LM Catalano, RT Barfield, R Cozad, G Wynn, ...
Proceedings of the National Academy of Sciences 110 (37), 14990-14994, 2013
Density matters: comparison of array platforms for detection of copy-number variation and copy-neutral abnormalities
H Mason-Suares, W Kim, L Grimmett, ES Williams, VL Horner, D Kunig, ...
Genetics in Medicine 15 (9), 706-712, 2013
Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest
N Acquavella, D Clever, Z Yu, M Roelke-Parker, DC Palmer, L Xi, ...
Cancer immunology research 3 (1), 37-47, 2015
Large-scale pharmacological profiling of 3D tumor models of cancer cells
LA Mathews Griner, X Zhang, R Guha, C McKnight, IS Goldlust, ...
Cell death & disease 7 (12), e2492-e2492, 2016
Drugs targeting tumor-initiating cells prolong survival in a post-surgery, post-chemotherapy ovarian cancer relapse model
BS Harrington, MK Ozaki, MW Caminear, LF Hernandez, E Jordan, ...
Cancers 12 (6), 1645, 2020
Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy
RC Jackson, GY Di Veroli, SB Koh, I Goldlust, FM Richards, DI Jodrell
PLoS computational biology 13 (5), e1005529, 2017
Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21
MK Kim, DJ Min, G Wright, I Goldlust, CM Annunziata
Oncotarget 5 (24), 12788, 2014
mQC: a heuristic quality-control metric for high-throughput drug combination screening
L Chen, K Wilson, I Goldlust, BT Mott, R Eastman, MI Davis, X Zhang, ...
Scientific Reports 6 (1), 37741, 2016
Matrix drug screen identifies synergistic drug combinations to augment smac mimetic activity in ovarian cancer
AM Noonan, A Cousins, D Anderson, KP Zeligs, K Bunch, L Hernandez, ...
Cancers 12 (12), 3784, 2020
No cell left behind: Residual ovarian spheroids drive recurrence and are sensitive to the pro-oxidant elesclomol
IS Goldlust, K Wilson, L Szabova, X Zhang, L Mathews-Griner, M Vias, ...
Cancer Research 76 (14_Supplement), 278-278, 2016
PARP inhibitors in ovarian cancer
IS Goldlust, E Guidice, J Lee
Seminars in Oncology, 2024
The spectrum of cell death in sarcoma
E Belyaeva, N Loginova, BA Schroeder, IS Goldlust, A Acharya, S Kumar, ...
Biomedicine & Pharmacotherapy 162, 114683, 2023
The Design of Theophylline Sensing Riboswitches in Agrobacteriumtumefaciens and Their Application in Reprogramming theVirA/VirG Two-Component System
IS Goldlust
The system can't perform the operation now. Try again later.
Articles 1–18